Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dosage optimization of treatments using population pharmacokinetic modeling and simulation.

Chimia - 1 Jan 2012

Guidi M, Arab-Alameddine Mona, Rotger Margalida, Aouri Manel, Telenti Amalio, Decosterd Laurent A, Buclin Thierry, Csajka Chantal

Abstract excerpt

Pharmacokinetic variability in drug levels represent for some drugs a major determinant of treatment success, since sub-therapeutic concentrations might lead to toxic reactions, treatment discontinuation or inefficacy. This is true for most antiretroviral drugs, which exhibit high inter-patient variability in their pharmacokinetics that has been partially explained by some genetic and non-genetic factors. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2B6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Drug Monitoring

Share to HIV Seropositivity

Share to Nevirapine

Share to Oxidoreductases, N-Demethylating

Share to Population

Source

Identifiers

PMID: 22867538
DOI: 10.2533/chimia.2012.291

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dosage optimization of treatments using population pharmacokinetic modeling and simulation.PMID 22867538Read ↗

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individualsSemantic proximity Read ↗

Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian PatientsSemantic proximity Read ↗

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.Semantic proximity Read ↗

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.Semantic proximity Read ↗

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).Semantic proximity Read ↗

Role of pharmacogenetics and clinical parameters on nevirapine plasma concertation among HIV-1 patients receiving Antiretroviral Therapy in KenyaSemantic proximity Read ↗

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Semantic proximity Read ↗

Population Approach to Efavirenz Therapy.Semantic proximity Read ↗

Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.Semantic proximity Read ↗

Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.